Redx Pharma

About Redx Pharma

Redx Pharma Plc, incorporated in 2010 and based in Macclesfield, UK, is a clinical-stage biotechnology company that discovers and develops small molecule drugs for fibrosis and cancer. The company's business model is centered on advancing its proprietary drug candidates to clinical proof of concept before exploring partnerships for late-stage development and commercialization, a strategy that has been validated through several high-profile collaborations.

The company's revenue is primarily generated through research collaboration agreements, milestone payments, and potential future royalties from its partners, which include major pharmaceutical companies like AstraZeneca and Jazz Pharmaceuticals. For instance, a partnership with Jazz on a Pan-RAF inhibitor program includes up to $203 million in various milestone payments plus royalties. Another significant partnership with Jazz involved the acquisition of Redx's KRAS inhibitor program, starting with a $10 million upfront payment and the potential for $870 million in future milestones and royalties.

Under the leadership of CEO Lisa Anson, who joined in June 2018, Redx has undergone a significant transformation. Anson, with a 20-year career at AstraZeneca, including serving as its UK President, brought extensive pharmaceutical leadership experience to steer Redx out of a financial crisis in 2017 and relaunch the company. Her background includes an MBA from INSEAD and a degree in Natural Sciences from Cambridge University. This leadership was instrumental in reshaping the company, which had to sell a promising BTK inhibitor program (now known as pirtobrutinib or LOXO-305) for $40 million during its administration period.

Redx's drug pipeline is focused on areas with high unmet medical needs. The lead fibrosis candidate, Zelasudil (RXC007), a selective ROCK2 inhibitor, is in Phase 2a trials for idiopathic pulmonary fibrosis (IPF). A second fibrosis candidate, RXC008, is a GI-targeted ROCK inhibitor for fibrostenotic Crohn's disease, which entered Phase 1 trials in early 2024. In oncology, the lead asset is RXC004, a Porcupine inhibitor for Wnt-ligand dependent cancers, which is also in Phase 2 trials. The company's strategy involves developing some assets in-house while partnering others to generate non-dilutive funding to advance its core programs.